Anna Berg

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood

Jacques J. M. van Dongen, Taku Seriu, E. Renate Panzer-Grümayer et al. · The Lancet · 1998 · 961 citations

Medicine, Hematology, Oncology +14

Phenotypic properties of transmitted founder HIV-1

Nicholas F. Parrish, Feng Gao, Hui Li et al. · Proceedings of the National Academy of Sciences · 2013 · 438 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004)

Willem A. Kamps, Henk van den Berg, Eva van den Berg et al. · The Lancet Oncology · 2009 · 248 citations

Medicine, Oncology, Pediatrics +11

Transmitted/Founder and Chronic Subtype C HIV-1 Use CD4 and CCR5 Receptors with Equal Efficiency and Are Not Inhibited by Blocking the Integrin α4β7

Nicholas F. Parrish, Craig B. Wilen, Lauren B. Banks et al. · PLoS Pathogens · 2012 · 148 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +17

Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the “BFM family” cooperative group

Anna Berg, Claus R. Bartram, Giuseppe Basso et al. · Medical and Pediatric Oncology · 1992 · 109 citations

Medicine, Hematology, Oncology +17